Correction of immune disturbances in chronic cerebral ischemia
Шулгинова А. А., Конопля А. И., Бyстрова Н. А., Гаврилиук В. П., Караулов А. В.
Медицинская иммунология
Т. 20, Вып. 3, С. 401-410
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.15789/1563-0625-2018-3-401-410
Аннотация:
The aim of the study was to determine efficiency of Glutoxim, aimed for correction of immune disorders. The drug was administered to the patients with chronic cerebral ischemia (CCI, Stage I and II) complicated by arterial hypertension. Increased contents of pro-And anti-inflammatory cytokines, IFNγ, IL- 2, G-CSF, and activation of the complement system have been revealed for these conditions, at both functional stages of the disease. The patients with stage II CCI showed elevated markers of oxygen-dependent activity in polymorphonuclear leukocytes (increased levels of spontaneous and stimulated nitroblue tetrazolium (NBT) reduction tests, phagocytic capacity and stimulation index of neutrophils). Stage I of chronic cerebral ischemia was characterized by normal values of NBT reduction tests and functional reserve of neutrophils, along with decreased stimulation index of neutrophils. Among 26 parameters of immune status, 73.1[%] and 80.8[%] of indices proved to be changed, respectively, in
Ключевые слова:
Chronic cerebral ischemia; Complement components; Cytokines; Glutoxim; Immune disorders
Язык текста: Русский
ISSN: 2313-741X
Шулгинова А. А.
Конопля А. И.
Бyстрова Н. А.
Гаврилиук В. П.
Караулов А. В. Александр Викторович 1953-
Shulginova A. A.
Konoplya A. I.
Bystrova N. A.
Gavriliuk V. P.
Karaulov A. V. Aleksandr Viktorovich 1953-
Correction of immune disturbances in chronic cerebral ischemia
Текст визуальный непосредственный
Медицинская иммунология
Санкт-Петербургское региональное отделение Российской ассоциации аллергологов и клинических иммунологов
Т. 20, Вып. 3 С. 401-410
2018
Статья
Chronic cerebral ischemia Complement components Cytokines Glutoxim Immune disorders
The aim of the study was to determine efficiency of Glutoxim, aimed for correction of immune disorders. The drug was administered to the patients with chronic cerebral ischemia (CCI, Stage I and II) complicated by arterial hypertension. Increased contents of pro-And anti-inflammatory cytokines, IFNγ, IL- 2, G-CSF, and activation of the complement system have been revealed for these conditions, at both functional stages of the disease. The patients with stage II CCI showed elevated markers of oxygen-dependent activity in polymorphonuclear leukocytes (increased levels of spontaneous and stimulated nitroblue tetrazolium (NBT) reduction tests, phagocytic capacity and stimulation index of neutrophils). Stage I of chronic cerebral ischemia was characterized by normal values of NBT reduction tests and functional reserve of neutrophils, along with decreased stimulation index of neutrophils. Among 26 parameters of immune status, 73.1[%] and 80.8[%] of indices proved to be changed, respectively, in